These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23423204)

  • 41. The novel oral anticoagulants: an update for the interventional radiologist.
    Crockett MT; Moynagh MR; Kavanagh EC
    AJR Am J Roentgenol; 2012 Sep; 199(3):W376-9. PubMed ID: 22915429
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical pharmacological aspects of new oral anticoagulants].
    Haschke M
    Ther Umsch; 2012 Nov; 69(11):657-60. PubMed ID: 23117669
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New directions in anticoagulation.
    Alpert JS
    Am J Med; 2012 Mar; 125(3):217-8. PubMed ID: 22340912
    [No Abstract]   [Full Text] [Related]  

  • 44. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anticoagulation therapy: Bleeding no worse with novel agents.
    Phillips R
    Nat Rev Cardiol; 2015 Jul; 12(7):381. PubMed ID: 25962977
    [No Abstract]   [Full Text] [Related]  

  • 46. New oral anticoagulants--a review.
    Ghanima W; Atar D; Sandset PM
    Tidsskr Nor Laegeforen; 2013 Oct; 133(18):1940-5. PubMed ID: 24084970
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emergency surgery and trauma in patients treated with the new oral anticoagulants: dabigatran, rivaroxaban, and apixaban.
    Moorman ML; Nash JE; Stabi KL
    J Trauma Acute Care Surg; 2014 Sep; 77(3):486-94; quiz 486-94. PubMed ID: 25159255
    [No Abstract]   [Full Text] [Related]  

  • 48. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
    Cuker A; Siegal DM; Crowther MA; Garcia DA
    J Am Coll Cardiol; 2014 Sep; 64(11):1128-39. PubMed ID: 25212648
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Laboratory monitoring of the non-vitamin K oral anticoagulants.
    Blann AD; Lip GY
    J Am Coll Cardiol; 2014 Sep; 64(11):1140-2. PubMed ID: 25212649
    [No Abstract]   [Full Text] [Related]  

  • 50. New orally active anticoagulants in critical care and anesthesia practice: the good, the bad and the ugly.
    Sehgal V; Bajwa SJ; Bajaj A
    Ann Card Anaesth; 2013; 16(3):193-200. PubMed ID: 23816673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.
    Baglin T; Keeling D; Kitchen S;
    Br J Haematol; 2012 Nov; 159(4):427-9. PubMed ID: 22970737
    [No Abstract]   [Full Text] [Related]  

  • 52. [New direct oral anticoagulants and venous thromboprophylaxis].
    Degirmenci SE; Steib A
    Rev Prat; 2013 Sep; 63(7):976-9. PubMed ID: 24167901
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Managing new oral anticoagulants in the intensive care unit.
    Gass JA; Weeks PA
    Crit Care Nurs Q; 2013; 36(4):390-9. PubMed ID: 24002428
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Atrial fibrillation: what the GP needs to know].
    Diener HC; Kaeufer T; Bode C
    MMW Fortschr Med; 2011 Sep; 153(38):44-7; quiz 48. PubMed ID: 21977796
    [No Abstract]   [Full Text] [Related]  

  • 55. [Bleeding and surgery in the treatment with new oral anticoagulants. The management can be complicated by the lack of specific antidotes].
    Dalén M; Hjemdahl P; Holmström M; Ivert T
    Lakartidningen; 2014 Jun 11-17; 111(24):1064-8. PubMed ID: 25129916
    [No Abstract]   [Full Text] [Related]  

  • 56. Renal risk stratification with the new oral anticoagulants (July 2013).
    Pazmiño P
    Cleve Clin J Med; 2013 Nov; 80(11):733-4. PubMed ID: 24186892
    [No Abstract]   [Full Text] [Related]  

  • 57. In reply.
    Fawole A
    Cleve Clin J Med; 2013 Nov; 80(11):734. PubMed ID: 24341084
    [No Abstract]   [Full Text] [Related]  

  • 58. Determination of the anti-F10a or anti-F2a generation action of rivaroxaban or dabigatran.
    Stief TW
    Blood Coagul Fibrinolysis; 2012 Oct; 23(7):619-21. PubMed ID: 22821003
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
    Spyropoulos AC; Douketis JD; Gerotziafas G; Kaatz S; Ortel TL; Schulman S;
    J Thromb Haemost; 2012 Apr; 10(4):692-4. PubMed ID: 22934291
    [No Abstract]   [Full Text] [Related]  

  • 60. [Pharmacodynamic and pharmacokinetic characteristics. Mechanism of action of the new oral anticoagulants].
    Roldán Schilling V; Vicente García V
    Med Clin (Barc); 2012 Oct; 139 Suppl 2():10-2. PubMed ID: 23498066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.